

PRODUCT INFORMATION



CP-EPS8-NLS (trifluoroacetate salt)

Item No. 41743

Peptide Sequence: Ac-GRKKRRQRRRPPQSK

Synonym: RKKGKKGKRK-NH₂
CP-Epidermal Growth Factor Receptor Kinase Substrate 8-NLS

MF: C₁₃₅H₂₅₆N₆₂O₃₀ • XCF₃COOH

FW: 3,227.9

Purity: ≥95% • XCF₃COOH

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

Ac—Gly—Arg—Lys—Lys—Arg—Arg—Gln—Arg—Arg—Arg—
Pro—Pro—Gln—Ser—Lys—Arg—Lys—Lys—Asn—Lys—
Lys—Gly—Lys—Arg—Lys—NH₂

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CP-EPS8-NLS (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the CP-EPS8-NLS (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. CP-EPS8-NLS (trifluoroacetate salt) is soluble (≥10 mg/ml) in DMSO.

Aqueous solutions of CP-EPS8-NLS (trifluoroacetate salt) can be prepared by directly dissolving the solid in aqueous buffers. CP-EPS8-NLS (trifluoroacetate salt) is soluble (≥10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

CP-EPS8-NLS is a cell-penetrating peptide inhibitor of epidermal growth factor receptor kinase substrate 8 (EPS8) nuclear translocation.¹ It induces apoptosis and cell cycle arrest in the G₀/G₁ phase in THP-1, HL-60, and U937 leukemia cells when used at a concentration of 70 μM. CP-EPS8-NLS (35 or 70 μM) reduces phosphorylated ERK, STAT3, and Akt levels in THP-1, HL-60, and U937 cells. It reduces tumor volume without affecting body weight in a U937 mouse xenograft model when administered at a dose of 55 mg/kg every other day. CP-EPS8-NLS (50 mg/kg every other day), alone or in combination with daunorubicin (Item No. 14159), decreases tumor volume in a KG-1 acute myeloid leukemia (AML) mouse xenograft model.

Reference

1. Chen, Y., Xie, X., Wu, A., *et al.* A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. *J. Exp. Ther. Cancer Res.* **37(1)**, 12 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/11/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM